Experimental Methods for Identifying Drug-Drug Interactions

Metabolism-mediated drug-drug interactions (DDI) refer to the interference of simultaneously administered drugs with each other's ADME (absorption, distribution, metabolism, and elimination) process by inducing or inhibiting the activities of drug-metabolizing enzymes and/or drug transporters. These interactions can significantly affect drug efficacy and safety, and thus it is imperative to identify and comprehend them during the drug development phase.

Types of Drug-Drug Interactions

• Pharmacokinetic interactions. These interactions involve changes in the absorption, distribution, metabolism, or excretion of drugs. For example, one drug may inhibit the activity of enzymes responsible for the metabolism of another drug, leading to increased systemic exposure and potential toxicity.
• Pharmacodynamic interactions. Pharmacodynamic interactions occur when drugs with similar or opposing pharmacological effects are co-administered, resulting in synergistic or antagonistic effects. For instance, the combination of two drugs with sedative properties may lead to enhanced sedation.
• Chemical interactions between drugs. These interactions occur when drugs react chemically in vitro (e.g. when mixed for use). For example, two drugs may produce new compounds when used together that affect the stability and efficacy of the drug.

In Vivo Experimental Methods for the Identification of DDIs

• Enzyme inhibition and induction assays. Predict drug metabolic interactions in vivo by analyzing the inhibition or induction of metabolic enzymes (e.g., cytochrome P450 enzymes) by the drug.
• Transporter protein assays. To assess the effects of drugs on transporter proteins (e.g., P-glycoprotein) and predict possible drug interactions during absorption, distribution, and excretion in vivo.
• Protein binding assays: predict drug distribution interactions in vivo by determining the extent of drug binding to plasma proteins.

In Vitro Experimental Methods for the Identification of DDIs

• Animal experiments on drug interactions. Two or more drugs are given simultaneously in an animal model, and changes in pharmacokinetic and pharmacodynamic parameters of the drugs in the animals are observed, to hypothesize the possible drug interactions.
• Clinical drug interaction experiment. In human clinical trials, drug interactions in the body are evaluated by administering two or more drugs and monitoring parameters such as blood concentrations, pharmacodynamic indices, and adverse reactions to the drugs.
• Observational study. Collecting data on patients' drug use, efficacy, and adverse reactions during actual clinical treatment and analyzing the risk of drug interactions through epidemiological methods.

Creative Bioarray Relevant Recommendations

Creative Bioarray provides high-quality drug-drug interaction services, including identification of drug-metabolizing enzymes, CYP and UGT inhibition assays, and inhibition studies towards less common metabolizing enzymes, such as MAO, FMO, NAT, AOX, and CES.